http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2022, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 10 May 2022 16:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/Press+Releases/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Visit StreetInsider.com at http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html for the full story. http://www.streetinsider.com/PRNewswire/Eiger+BioPharmaceuticals+and+AnGes+Announce+Exclusive+Partnership+for+Regulatory+Approval+and+Commercialization+of+Zokinvy%C2%AE+%28lonafarnib%29+in+Japan/20051268.html Tue, 10 May 2022 16:30:00 -0400 4563 A.31066700 A.60012004 EIGR O.04957640 O.13746763 http://www.streetinsider.com/Press+Releases/AnGes+Obtains+Conditional+Approval+in+Japan+for+HGF+Gene+Therapy+to+Treat+Critical+Limb+Ischemia/15343496.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/AnGes+Obtains+Conditional+Approval+in+Japan+for+HGF+Gene+Therapy+to+Treat+Critical+Limb+Ischemia/15343496.html for the full story. http://www.streetinsider.com/Press+Releases/AnGes+Obtains+Conditional+Approval+in+Japan+for+HGF+Gene+Therapy+to+Treat+Critical+Limb+Ischemia/15343496.html Thu, 04 Apr 2019 22:00:00 -0400 4563 http://www.streetinsider.com/Press+Releases/Vasomune+Therapeutics+and+AnGes%2C+Inc.+enter+into+a+Multi-Million+Dollar+Global+Co-Development+Agreement+to+Advance+an+Innovative+Platform+Targeting+Vascular+Leakage/14450780.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Vasomune+Therapeutics+and+AnGes%2C+Inc.+enter+into+a+Multi-Million+Dollar+Global+Co-Development+Agreement+to+Advance+an+Innovative+Platform+Targeting+Vascular+Leakage/14450780.html for the full story. http://www.streetinsider.com/Press+Releases/Vasomune+Therapeutics+and+AnGes%2C+Inc.+enter+into+a+Multi-Million+Dollar+Global+Co-Development+Agreement+to+Advance+an+Innovative+Platform+Targeting+Vascular+Leakage/14450780.html Tue, 31 Jul 2018 07:00:00 -0400 4563 http://www.streetinsider.com/Press+Releases/Vasomune+Therapeutics+and+AnGes%2C+Inc.+enter+into+a+Multi-Million+Dollar+Global+Co-Development+Agreement+to+Advance+an+Innovative+Platform+Targeting+Vascular+Leakage/14450847.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Vasomune+Therapeutics+and+AnGes%2C+Inc.+enter+into+a+Multi-Million+Dollar+Global+Co-Development+Agreement+to+Advance+an+Innovative+Platform+Targeting+Vascular+Leakage/14450847.html for the full story. http://www.streetinsider.com/Press+Releases/Vasomune+Therapeutics+and+AnGes%2C+Inc.+enter+into+a+Multi-Million+Dollar+Global+Co-Development+Agreement+to+Advance+an+Innovative+Platform+Targeting+Vascular+Leakage/14450847.html Tue, 31 Jul 2018 07:00:00 -0400 4563 http://www.streetinsider.com/Press+Releases/AnGes+Announces+First+Patient+Treated+with+NF-kappa+B+Decoy+in+Phase+Ib+Study+to+Treat+Discogenic+Low+Back+Pain/13874889.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/AnGes+Announces+First+Patient+Treated+with+NF-kappa+B+Decoy+in+Phase+Ib+Study+to+Treat+Discogenic+Low+Back+Pain/13874889.html for the full story. http://www.streetinsider.com/Press+Releases/AnGes+Announces+First+Patient+Treated+with+NF-kappa+B+Decoy+in+Phase+Ib+Study+to+Treat+Discogenic+Low+Back+Pain/13874889.html Tue, 27 Feb 2018 19:31:00 -0400 4563 A.06822034 http://www.streetinsider.com/Press+Releases/AnGes+Announces+First+Patient+Treated+with+NF-kappa+B+Decoy+in+Phase+Ib+Study+to+Treat+Discogenic+Low+Back+Pain/13874889.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/AnGes+Announces+First+Patient+Treated+with+NF-kappa+B+Decoy+in+Phase+Ib+Study+to+Treat+Discogenic+Low+Back+Pain/13874889.html for the full story. http://www.streetinsider.com/Press+Releases/AnGes+Announces+First+Patient+Treated+with+NF-kappa+B+Decoy+in+Phase+Ib+Study+to+Treat+Discogenic+Low+Back+Pain/13874889.html Tue, 27 Feb 2018 19:31:00 -0400 4563 A.06822034 http://www.streetinsider.com/Press+Releases/AnGes+Submits+Application+for+Marketing+Approval+to+PMDA+for+HGF+gene+therapy+for+Critical+Limb+Ischemia/13710048.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/AnGes+Submits+Application+for+Marketing+Approval+to+PMDA+for+HGF+gene+therapy+for+Critical+Limb+Ischemia/13710048.html for the full story. http://www.streetinsider.com/Press+Releases/AnGes+Submits+Application+for+Marketing+Approval+to+PMDA+for+HGF+gene+therapy+for+Critical+Limb+Ischemia/13710048.html Mon, 22 Jan 2018 22:11:00 -0400 4563 A.13495780 http://www.streetinsider.com/Press+Releases/AnGes+Submits+Application+for+Marketing+Approval+to+PMDA+for+HGF+gene+therapy+for+Critical+Limb+Ischemia/13710048.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/AnGes+Submits+Application+for+Marketing+Approval+to+PMDA+for+HGF+gene+therapy+for+Critical+Limb+Ischemia/13710048.html for the full story. http://www.streetinsider.com/Press+Releases/AnGes+Submits+Application+for+Marketing+Approval+to+PMDA+for+HGF+gene+therapy+for+Critical+Limb+Ischemia/13710048.html Mon, 22 Jan 2018 22:11:00 -0400 4563 A.13495780